Bumadizone Calcium

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 329210

CAS#: 34461-73-9 (calcium)

Description: Bumadizone Calcium, also known as Eumotol and B-64114, is a non-steroidal anti-inflammatory drug used to treat pain and arthritis.


Price and Availability

Size
Price

Size
Price

Size
Price

Bumadizone Calcium (Eumotol, B-64114) is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 329210
Name: Bumadizone Calcium
CAS#: 34461-73-9 (calcium)
Chemical Formula: C38H42CaN4O6
Exact Mass:
Molecular Weight: 690.854
Elemental Analysis: C, 66.07; H, 6.13; Ca, 5.80; N, 8.11; O, 13.89


Related CAS #: 3583-64-0 (free acid)   34461-73-9 (Calcium).  

Synonym: Bumadizone Calcium; B-64114; B-64114; B-64114; Eumotol;

IUPAC/Chemical Name: calcium 2-(1,2-diphenylhydrazine-1-carbonyl)hexanoate

InChi Key: RKINNRASCJRSHD-UHFFFAOYSA-L

InChi Code: InChI=1S/2C19H22N2O3.Ca/c2*1-2-3-14-17(19(23)24)18(22)21(16-12-8-5-9-13-16)20-15-10-6-4-7-11-15;/h2*4-13,17,20H,2-3,14H2,1H3,(H,23,24);/q;;+2/p-2

SMILES Code: O=C([O-])C(CCCC)C(N(C1=CC=CC=C1)NC2=CC=CC=C2)=O.O=C([O-])C(CCCC)C(N(C3=CC=CC=C3)NC4=CC=CC=C4)=O.[Ca+2]


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information



References

1: Goto W, Ichikawa M, Tanaka E, Hara H, Araie M. Bunazosin hydrochloride reduces glutamate-induced neurotoxicity in rat primary retinal cultures. Brain Res. 2004 Apr 2;1003(1-2):130-7. PubMed PMID: 15019572.

2: Kobayashi H, Kobayashi K, Okinami S. Efficacy of bunazosin hydrochloride 0.01% as adjunctive therapy of latanoprost or timolol. J Glaucoma. 2004 Feb;13(1):73-80. PubMed PMID: 14704548.

3: Yoshikawa K, Katsushima H, Kimura T, Yamagishi K, Yamabayashi S. Addition of or switch to topical bunazosin hydrochloride in elderly patients with normal-tension glaucoma: A one-year follow-up study. Jpn J Ophthalmol. 2006 Sep-Oct;50(5):443-8. PubMed PMID: 17013697.

4: Okada Y, Ichikawa M, Ishii K, Hara H. Effects of topically instilled bunazosin hydrochloride and other ocular hypotensive drugs on endothelin-1-induced constriction in rabbit retinal arteries. Jpn J Ophthalmol. 2004 Sep-Oct;48(5):465-9. PubMed PMID: 15486769.

5: Hara H, Ichikawa M, Oku H, Shimazawa M, Araie M. Bunazosin, a selective alpha1-adrenoceptor antagonist, as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage. Cardiovasc Drug Rev. 2005 Spring;23(1):43-56. Review. PubMed PMID: 15867947.

6: Mochizuki Y, Oishi M, Takasu T. Effects of bunazosin hydrochloride sustained-release formulation on cerebral circulation. Int Angiol. 2000 Mar;19(1):35-8. PubMed PMID: 10853683.

7: Akaishi T, Takagi Y, Matsugi T, Ishida N, Hara H, Kashiwagi K. Effects of bunazosin hydrochloride on ciliary muscle constriction and matrix metalloproteinase activities. J Glaucoma. 2004 Aug;13(4):312-8. PubMed PMID: 15226660.

8: Goto W, Oku H, Okuno T, Sugiyama T, Ikeda T. Amelioration by topical bunazosin hydrochloride of the impairment in ocular blood flow caused by nitric oxide synthase inhibition in rabbits. J Ocul Pharmacol Ther. 2003 Feb;19(1):63-73. PubMed PMID: 12648305.

9: Hu WY, Fukuda N, Soma M, Izumi Y, Kanmatsuse K. Bunazosin hydrochloride inhibits exaggerated growth of vascular smooth muscle cells from spontaneously hypertensive rats by suppressing the response to growth factors. J Cardiovasc Pharmacol. 1998 Dec;32(6):975-82. PubMed PMID: 9869504.

10: Yang SC, Tsai WI, Liau CS, Wang TD. Effect of 8-Week Combination Therapy with an Extended-Release α1-Blocker (Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan) in Patients with Stage 1 or 2 Essential Hypertension. Acta Cardiol Sin. 2013 Jan;29(1):11-8. PubMed PMID: 27122680; PubMed Central PMCID: PMC4804956.

11: Ichikawa M, Okada Y, Asai Y, Hara H, Ishii K, Araie M. Effects of topically instilled bunazosin, an alpha1-adrenoceptor antagonist, on constrictions induced by phenylephrine and ET-1 in rabbit retinal arteries. Invest Ophthalmol Vis Sci. 2004 Nov;45(11):4041-8. PubMed PMID: 15505054.

12: Goto W, Oku H, Okuno T, Sugiyama T, Ikeda T. Amelioration of endothelin-1-induced optic nerve head ischemia by topical bunazosin. Curr Eye Res. 2005 Feb;30(2):81-91. PubMed PMID: 15814466.

13: Lee AS, Chen WP, Su MJ. Comparison of the cardiac electrophysiological effects between doxazosin and bunazosin. J Biomed Sci. 2008 Jul;15(4):519-28. doi: 10.1007/s11373-008-9249-8. PubMed PMID: 18427952.

14: Sugiyama T, Oku H, Moriya S, Shimizu K, Azuma I. [Evaluation of bunazosin hydrochloride with a model of ocular circulation disturbance induced by endothelin-1]. Nippon Ganka Gakkai Zasshi. 1994 Jan;98(1):63-8. Japanese. PubMed PMID: 7906490.

15: Aihara M, Araie M, Kaburaki T, Shirato S. [Effects of long-term application of bunazosin hydrochloride eye drops on the aqueous flow rate and blood-aqueous barrier permiability in rabbit eyes]. Nippon Ganka Gakkai Zasshi. 1994 Jun;98(6):540-4. Japanese. PubMed PMID: 7913288.